JonesResearch downgraded Impel Pharmaceuticals to Hold from Buy without a price target. Impel’s quarterly filing reaffirms substantial doubt about the company’s ability to continue as a going concern, the analyst tells investors in a research note. While Trudhesa script demand continued to improve, there are “limited reasons for optimism” given the risk of default and lack of clarity on the company’s potential path to sustainability, says the firm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMPL: